A general preparation method for increasing drug loading rate by encapsulating metal ions in ACC

By synthesizing metal-ACC nanoparticles by gas-phase diffusion method in ethanol, the problems of complex synthesis and low loading rate in the prior art are solved, and efficient drug loading and stability are achieved, which are suitable for tumor-targeted treatment.

CN116350791BInactive Publication Date: 2024-11-12TSINGHUA UNIVERSITY
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202310233399.7
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2023-03-13
Publication Date
2024-11-12
Estimated Expiration
Not applicable · inactive patent

AI Technical Summary

Technical Problem

In the prior art, the method of synthesizing drug-ACC nanoparticles is relatively complex and is not conducive to preservation. The synthesis technology of metal ions incorporated into ACC is incomplete, resulting in limited drug loading and difficult to achieve efficient tumor targeted treatment.

Method used

Metal-ACC nanoparticles were synthesized in ethanol by gas phase diffusion. Metal ions and drugs were incorporated into ACC through a single mineralization process to form uniform granular nanoparticles, which increased the drug loading rate and existed stably in the ethanol environment.

Benefits of technology

It realizes simple and easy-to-use metal-ACC nanoparticle synthesis, improves drug loading rate, uniform product particle size, is suitable as a tumor-targeted therapy carrier, and has good biocompatibility and stability in the field of biomedicine.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN116350791B_ABST
    Figure CN116350791B_ABST
Patent Text Reader

Abstract

The present application provides a general preparation method for increasing the drug loading rate by encapsulating metal ions with amorphous calcium carbonate (ACC). In the preparation process of the metal ion and / or drug-loaded ACC nanoparticles of the present application, the metal ions and the drug are loaded by a single mineralization in an ethanol solution of a calcium salt and a metal salt and / or the drug. The addition of metal ions can increase the drug loading rate in ACC, and the process is simple and easy. At the same time, the synthesized nanoparticles have a uniform particle size and are suitable for use in the fields of tumor targeted therapy.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The patent of the present invention belongs to the technical field of nanomaterial preparation process. Specifically, the present application provides a general preparation method for enhancing drug loading rate by encapsulating metal ions with amorphous calcium carbonate (ACC) as well as corresponding nanoparticles and applications. Background Art

[0002] Calcium carbonate is a compound that exists in large quantities in nature and is widely used in industrial fields such as ceramics, construction, and biomedicine. Calcium carbonate in nature usually exists in crystalline form, mainly including calcite, vaterite, and aragonite. Amorphous calcium carbonate (ACC) is an extremely unstable form of existence. It will quickly dissolve and reprecipitate to form a crystalline structure in an aqueous environment within a few minutes. The properties of ACC are very different from those of crystalline calcium carbonate. Due to its good solubility, strong pH sensitivity, porosity, and biocompatibility, ACC nanoparticles can play an important role in the targeted treatment of tumors and other fields.

[0003] By utilizing ACC's sensitivity to pH, targeted release of tumor therapeutic drugs can be achieved. ACC is relatively stable in a high pH environment, but rapidly decomposes in a low pH environment. The pH around malignant tumor tissue is usually slightly lower than that of normal tissue, so ACC can be targeted and decomposed around tumor tissue. At the same time, by utilizing the porosity of ACC, it can be used to carry tumor therapeutic drugs, and release the drugs when it decomposes around tumor tissue, thereby achieving the purpose of targeted therapy. Compared with traditional chemotherapy regimens, the regimen using ACC to carry drugs has high targeting, and the decomposition products of ACC themselves are harmless to the human body and cause little damage to normal human tissues.

[0004] The methods for preparing ACC mainly include the chemical coprecipitation method that directly mixes the calcium salt aqueous solution and the carbonate aqueous solution under certain conditions to generate ACC by double decomposition reaction; the gas phase diffusion method that uses NH4HCO3 to decompose at above 30°C to generate CO2 and NH3, which diffuse in a closed system and dissolve in CaCl2 ethanol solution to form ACC; the reverse microemulsion method that uses surfactants to form an emulsion of calcium salt and carbonate aqueous solution (water phase) in an organic solvent (oil phase) and react to generate ACC; the dimethyl carbonate decomposition method that uses hydrolysis of dimethyl carbonate to provide carbonic acid and calcium salt to generate ACC; the Kitano method that uses calcium bicarbonate solution to slowly decompose to generate ACC; and the ball milling method that uses mechanical crushing of calcite under the stabilization of Na2CO3, etc. Among them, the gas phase diffusion method has the advantages of good ACC dispersibility, uniform particle size, stable and controllable reaction process, and simple operation. It is the most commonly used preparation method in biomedicine.

[0005] In order to achieve targeted tumor therapy, it is necessary to utilize the porosity of ACC to achieve drug loading and synthesize drug-containing ACC nanoparticles. At present, studies have shown that the drug loading rate of pure ACC is limited to about 80%, and the drug loading rate of ACC can be increased by incorporating metal ions (such as Cu). In addition, some studies have suggested that adding Mg and Gd ions during the synthesis process can improve the stability of ACC. Therefore, it is of great research significance to simply and quickly synthesize drug-containing and metal ion-containing ACC nanoparticles.

[0006] Patent CN104261450B proposes to synthesize ACC nanoparticles with uniform particle size by using the vapor diffusion method, and to control the particle size by adjusting the concentration of the CaCl2 ethanol solution, providing a basic method for synthesizing ACC particles.

[0007] Patent CN102335141B proposes a method for preparing nano calcium carbonate-adriamycin, which uses a chemical coprecipitation method to mix CaCl2, adriamycin and Na2CO3 solution under mechanical vigorous stirring conditions to synthesize calcium carbonate-adriamycin particles with a particle size of about 100nm. This synthesis method requires multiple mechanical stirring to varying degrees, centrifugal re-dissolution, etc., and the operation requirements are relatively complicated. At the same time, ACC has extremely poor stability in an aqueous solution environment, and cannot be preserved after synthesis by this method.

[0008] Patent CN102895664A proposes a method for synthesizing Gd-stabilized ACC, which uses a chemical coprecipitation method to mix CaCl2, GdCl3 and Na2CO3 aqueous solution under the stabilization of PAA to synthesize ACC-Gd. This method greatly improves the stability of ACC, and the magnetism of Gd makes it usable as an MRI contrast agent. However, the morphology of ACC-Gd synthesized by this method is generally network-like rather than granular, which is not conducive to in vivo transportation and rapid targeted release of drugs as a drug carrier.

[0009] Patent CN108069451B proposes a method for synthesizing ultrafine ACC in an alcohol-water mixed system: adding a certain amount of alcohol and magnesium salt solution to a soluble amino acid calcium salt or a soluble calcium salt-ammonia solution, and passing CO2 gas. The ACC synthesized by this method can be stable in an aqueous environment for more than three days. However, the Mg content of the ACC synthesized by this method is 2+ Did not participate in the reaction, and no Mg was detected in the final product 2+ existence.

[0010] In summary, the current method of synthesizing drug-ACC nanoparticles is relatively complicated and not conducive to preservation. There is no mature method for synthesizing them in an ethanol environment using the vapor diffusion method. The synthesis technology of metal ion incorporation into ACC is also not perfect, and there are problems such as metal ions failing to enter the ACC structure and destroying the ACC granular structure. There is no systematic study on the general strategy of increasing drug loading rate using metal ions. Therefore, how to synthesize metal-ACC nanoparticles and anti-tumor drug-ACC nanoparticles by a simple and fast method, increase the drug loading rate by incorporating metal ions, and thus achieve more efficient tumor targeted therapy, is an urgent problem to be solved. Summary of the invention

[0011] In view of the defects of the prior art and the above-mentioned needs, the purpose of the present invention is to provide a method for synthesizing metal-ACC nanoparticles and drug-ACC nanoparticles. The method is based on the gas phase synthesis method of ACC and can achieve the incorporation of metal ions and drugs through only one mineralization. The addition of metal ions can increase the loading rate of drugs in ACC, and the process is simple and easy. At the same time, the synthesized nanoparticles have uniform particle size and can be widely used in fields such as tumor targeted therapy.

[0012] In one aspect, the present application provides a method for enhancing drug loading rate by encapsulating metal ions in ACC, wherein the method prepares metal ion and / or drug-ACC nanoparticles, and the method comprises:

[0013] 1) dissolving a calcium salt and a metal salt and / or a drug solid in alcohol, preferably ethanol, at room temperature to obtain an ethanol solution of metal ions-calcium, drug-calcium or metal ions-drug-calcium;

[0014] 2) pouring the solution obtained in step 1) into a container and sealing it, wherein one or more vent holes are provided on the sealed container;

[0015] 3) placing the ammonium bicarbonate solid in the same vacuum container as the container in step 2);

[0016] 4) Mineralization;

[0017] 5) Taking out the suspension in the container, centrifuging to obtain metal-ACC particles, drug-ACC particles or metal-drug-ACC particles and redispersing them in ethanol.

[0018] The container includes but is not limited to beakers, flasks, and petri dishes made of various materials; the sealing method includes but is not limited to sealing covers and sealing films; the size and number of the vents thereon may be determined by those skilled in the art based on the mineralization time, type of metal salt, temperature, etc., so as to allow an appropriate amount of carbon dioxide to enter the container for reaction.

[0019] As an example, ammonium bicarbonate solid is used in a six-well plate, but other suitable containers may be used.

[0020] Furthermore, the calcium salt is calcium chloride, preferably anhydrous calcium chloride; preferably, the concentration of the calcium salt in step 1) is 1.50 mg / ml.

[0021] Furthermore, the metal salt is selected from one or more of magnesium chloride, ferric chloride, manganous chloride, chromium chloride, cupric chloride, nickel chloride, zinc chloride, palladium chloride, cobalt nitrate, molybdenum chloride, gadolinium chloride and hydrates thereof.

[0022] Furthermore, the amount of ammonium bicarbonate in step 3) is 10 g for each beaker in step 2); when there are multiple beakers in the same vacuum dish, the amount of ammonium bicarbonate is increased by a corresponding multiple and placed on the same six-well plate.

[0023] Furthermore, the drug is selected from one or more of syringin, mangostin, doxorubicin hydrochloride, mitoxantrone, shikonin, paclitaxel, indocyanine green, oxaliplatin, and hydroxycamptothecin.

[0024] Furthermore, the drug concentration in step 1) is 0.01 mg / ml-1.00 mg / ml; preferably, when the drug is syringin and mangostin, the drug concentration in step 1) is 0.05 mg / ml, and when the drug is doxorubicin hydrochloride, mitoxantrone, shikonin, paclitaxel, indocyanine green, oxaliplatin, or hydroxycamptothecin, the drug concentration in step 1) is 0.10 mg / ml.

[0025] Hydrates of the above-mentioned metal salts include, but are not limited to, manganous chloride tetrahydrate, chromium chloride hexahydrate, cupric chloride dihydrate, nickel chloride hexahydrate, cobalt nitrate hexahydrate, gadolinium chloride hexahydrate, and the like.

[0026] Furthermore, the mineralization is carried out at a constant temperature of 35-40°C, preferably 37°C, and for 36-72 hours, preferably 72 hours.

[0027] Furthermore, the centrifugal speed is 5000-10000 rpm, preferably 8000 rpm; the time is 5-20 min, preferably 10 min.

[0028] On the other hand, the present application provides the use of the above-mentioned metal ion and / or drug-ACC nanoparticles or their preparation methods in the preparation of drugs for treating tumors.

[0029] Beneficial effects:

[0030] 1) The synthesis method of the present application is simple to operate. The incorporation of metal ions and drugs is carried out simultaneously with the synthesis of ACC. The preparation can be completed through only one mineralization process. There is no need to perform additional loading operations after the mineralization synthesis of ACC, which saves a lot of time.

[0031] 2) The product synthesized by the method of the present application can form dispersed particles with uniform particle size. Depending on the substance incorporated, the particle size is between 25-130 nm, and is suitable as a carrier for transporting drugs in the human body.

[0032] 3) The incorporation of metal ions can effectively improve the loading efficiency of drugs and is an ideal drug delivery carrier.

[0033] 4) The method of the present application is not only applicable to the loading of a single metal ion, but also to the loading of multiple metal ions.

[0034] 5) The synthesis method of the present application is carried out in an ethanol phase, and ACC can be stably present and can be stored for a long time before further operation without being transferred to other environments.

[0035] 6) The raw materials used in the synthesis process of the present application are in line with the concept of green environmental protection, have no biological toxicity, have good biocompatibility, and are suitable for application in the field of biomedicine.

[0036] In summary, the preparation method of the present application is improved on the basis of the vapor diffusion synthesis method of ACC. Metal-ACC nanoparticles and drug-ACC nanoparticles are synthesized by one-time mineralization. The synthesis method has the advantages of being simple and easy, green and environmentally friendly, and easy to preserve the product. The morphology of the obtained product meets the requirements for the transportation of drug carriers in the human body, and has important application value in the fields of tumor targeted therapy. BRIEF DESCRIPTION OF THE DRAWINGS

[0037] Figure 1 : SEM characterization of metal-ACC nanoparticles;

[0038] Figure 2 : Scanning electron microscopy characterization of drug-ACC nanoparticles;

[0039] Figure 3 :Transmission electron microscopy characterization of metal-drug-ACC nanoparticles;

[0040] Figure 4 :Transmission electron microscopy characterization of Cu-DOX-ACC nanoparticles;

[0041] Figure 5 : SEM characterization of CuCo-ACC nanoparticles.

[0042] Figure 6 : Scanning electron microscopy of MnZn-ACC nanoparticles.

[0043] Figure 7 : X-ray diffraction patterns of metal-ACC nanoparticles.

[0044] Figure 8 : Stability test results of Cu-ACC nanoparticles. DETAILED DESCRIPTION

[0045] The following examples are provided to facilitate a better understanding of the present invention, but are not limited thereto. These examples are only used for illustrative purposes and in no way limit the scope of protection of the present invention.

[0046] Example 1

[0047] (1) Add 150 mg of CaCl2 solid, 39.3 mg of Co(NO3)2·6H2O solid and 100 ml of ethanol into a beaker and stir until fully dissolved. Then seal the beaker and evenly poke some small holes on the sealing film.

[0048] (2) Weigh 10 g of NH4HCO3 solid and place it on a six-well plate.

[0049] (3) Place the beaker and the six-well plate in the same vacuum dish and place it in a 37°C incubator for mineralization for 72 hours.

[0050] (4) Take out the beaker, centrifuge at 8000 rpm for 10 min, collect the Co-ACC and disperse it again in 10 ml of ethanol. TEM characterization shows that the product is in the form of dispersed particles with a particle size of about 80 nm and a relatively uniform particle size. Figure 1 shown.

[0051] (5) X-ray diffraction patterns show that the nanoparticles are amorphous calcium carbonate structures, such as Figure 7 shown.

[0052] Example 2

[0053] (1) Add 150 mg of CaCl2 solid, 26.7 mg of MnCl2·4H2O solid and 100 ml of ethanol into a beaker and stir until fully dissolved. Then seal the beaker and evenly poke some small holes on the sealing film.

[0054] (2) Weigh 10 g of NH4HCO3 solid and place it on a six-well plate.

[0055] (3) Place the beaker and the six-well plate in the same vacuum dish and place it in a 37°C incubator for mineralization for 72 hours.

[0056] (4) Take out the beaker, centrifuge at 8000 rpm for 10 min, collect the Mn-ACC and disperse it again in 10 ml of ethanol. TEM characterization shows that the product is in the form of dispersed particles with a particle size of about 25 nm and a relatively uniform particle size. Figure 1 shown.

[0057] (5) X-ray diffraction patterns show that the nanoparticles are amorphous calcium carbonate structures, such as Figure 7 shown.

[0058] Example 3

[0059] (1) Add 150 mg of CaCl2 solid, 36.9 mg of MoCl5 solid and 100 ml of ethanol into a beaker, stir until fully dissolved, seal the beaker and evenly poke some small holes on the sealing film.

[0060] (2) Weigh 10 g of NH4HCO3 solid and place it on a six-well plate.

[0061] (3) Place the beaker and the six-well plate in the same vacuum dish and place it in a 37°C incubator for mineralization for 36 hours.

[0062] (4) Take out the beaker, centrifuge at 8000 rpm for 10 min, collect Mo-ACC and disperse it again in 10 ml of ethanol. TEM characterization shows that the product is in the form of dispersed particles with slightly uneven particle size distribution. Most of the particles are concentrated around 50 nm, and a small number of particles have a particle size of 100 nm. Figure 1 shown.

[0063] (5) X-ray diffraction patterns show that the nanoparticles are amorphous calcium carbonate structures, such as Figure 7 shown.

[0064] Example 4

[0065] (1) Add 150 mg of CaCl2 solid, 23.9 mg of PdCl2 solid and 100 ml of ethanol into a beaker and stir until fully dissolved. Seal the beaker and evenly poke some small holes on the sealing film.

[0066] (2) Weigh 10 g of NH4HCO3 solid and place it on a six-well plate.

[0067] (3) Place the beaker and the six-well plate in the same vacuum dish and place it in a 37°C incubator for mineralization for 72 hours.

[0068] (4) Take out the beaker, centrifuge at 8000 rpm for 10 min, collect Pd-ACC and disperse it again in 10 ml of ethanol. TEM characterization shows that the product is in the form of dispersed particles with a particle size of about 130 nm and a relatively uniform particle size. Figure 1 shown.

[0069] Example 5

[0070] (1) Add 150 mg of CaCl2 solid, 18.4 mg of ZnCl2·4H2O solid and 100 ml of ethanol into a beaker and stir until fully dissolved. Seal the beaker and evenly poke some small holes on the sealing film.

[0071] (2) Weigh 10 g of NH4HCO3 solid and place it on a six-well plate.

[0072] (3) Place the beaker and the six-well plate in the same vacuum dish and place it in a 37°C incubator for mineralization for 36 hours.

[0073] (4) Take out the beaker, centrifuge at 8000 rpm for 10 min, collect Mo-ACC and disperse it again in 10 ml of ethanol. TEM characterization shows that the product is in the form of dispersed particles with a particle size of about 100 nm and a relatively uniform particle size. Figure 1 shown.

[0074] (5) X-ray diffraction patterns show that the nanoparticles are amorphous calcium carbonate structures, such as Figure 7 shown.

[0075] Example 6

[0076] (1) Add 150 mg of CaCl2 solid, 13.4 mg of CuCl2 solid and 100 ml of ethanol into a beaker, stir until fully dissolved, seal the beaker and evenly poke some small holes on the sealing film.

[0077] (2) Weigh 10 g of NH4HCO3 solid and place it on a six-well plate.

[0078] (3) Place the beaker and the six-well plate in the same vacuum dish and place it in a 37°C incubator for mineralization for 36 hours.

[0079] (4) Take out the beaker, centrifuge at 8000 rpm for 10 min, collect Mo-ACC and disperse it again in 10 ml of ethanol. TEM characterization shows that the product is in the form of dispersed particles with a particle size of about 100 nm and a relatively uniform particle size. Figure 1 shown.

[0080] (5) After long-term storage in ethanol solvent for 6 months, the nanoparticles showed high stability through transmission electron microscopy images, and no morphological and structural changes occurred, such as Figure 8 shown.

[0081] Example 7

[0082] (1) Add 150 mg of solid CaCl2, 9.5 mg of solid MgCl2 and 100 ml of ethanol into a beaker, stir until fully dissolved, seal the beaker and evenly poke some small holes on the sealing film.

[0083] (2) Weigh 10 g of NH4HCO3 solid and place it on a six-well plate.

[0084] (3) Place the beaker and the six-well plate in the same vacuum dish and place it in a 37°C incubator for mineralization for 36 hours.

[0085] (4) Take out the beaker, centrifuge at 8000 rpm for 10 min, collect Mo-ACC and disperse it again in 10 ml of ethanol. TEM characterization shows that the product is in the form of dispersed particles with a particle size of about 100 nm and a relatively uniform particle size. Figure 1 shown.

[0086] Example 8

[0087] (1) Add 150 mg of solid CaCl2, 5 mg of solid Syringin and 100 ml of ethanol into a beaker and stir until fully dissolved. Seal the beaker and evenly poke some small holes on the sealing film.

[0088] (2) Weigh 10 g of NH4HCO3 solid and place it on a six-well plate.

[0089] (3) Place the beaker and the six-well plate in the same vacuum dish and place it in a 37°C incubator for mineralization for 72 hours.

[0090] (4) Take out the beaker, centrifuge at 8000 rpm for 10 min, collect Syringin@ACC and disperse it again in 10 ml of ethanol. TEM characterization shows that the product is in the form of dispersed particles with a particle size of about 90 nm and a relatively uniform particle size. Figure 2 shown.

[0091] Example 9

[0092] (1) Add 150 mg of CaCl2 solid, 10 mg of Doxorubicin solid and 100 ml of ethanol into a beaker and stir until fully dissolved. Then seal the beaker and evenly poke some small holes on the sealing film.

[0093] (2) Weigh 10 g of NH4HCO3 solid and place it on a six-well plate.

[0094] (3) Place the beaker and the six-well plate in the same vacuum dish and place it in a 37°C incubator for mineralization for 72 hours.

[0095] (4) Take out the beaker, centrifuge at 8000 rpm for 10 min, collect DOX@ACC and disperse it again in 10 ml of ethanol. TEM characterization shows that the product is in the form of dispersed particles with a particle size of about 50 nm. At the same time, there are a large number of fragmented substances that have not been granulated, such as Figure 2 shown.

[0096] (5) The drug loading rate test result was 82%.

[0097] Example 10

[0098] (1) Add 150 mg of solid CaCl2, 10 mg of solid Hydroxycamptothecin and ethanol into a 100 ml beaker, stir until fully dissolved, seal the beaker and evenly poke some small holes on the sealing film.

[0099] (2) Weigh 10 g of NH4HCO3 solid and place it on a six-well plate.

[0100] (3) Place the beaker and the six-well plate in the same vacuum dish and place it in a 37°C incubator for mineralization for 72 hours.

[0101] (4) Take out the beaker, centrifuge at 8000 rpm for 10 min, collect Hydroxycamptothecin@ACC and disperse it again in 10 ml of ethanol. TEM characterization shows that the product is in the form of dispersed particles with a particle size of about 50 nm. The particle size is relatively uniform. At the same time, there are a small number of small particles around the particles, such as Figure 2 shown.

[0102] Embodiment 11

[0103] (1) Add 150 mg of solid CaCl2, 10 mg of solid Mitoxantrone and 100 ml of ethanol into a beaker and stir until fully dissolved. Then seal the beaker and evenly poke some small holes on the sealing film.

[0104] (2) Weigh 10 g of NH4HCO3 solid and place it on a six-well plate.

[0105] (3) Place the beaker and the six-well plate in the same vacuum dish and place it in a 37°C incubator for mineralization for 72 hours.

[0106] (4) Take out the beaker, centrifuge at 8000 rpm for 10 min, collect MXT@ACC and disperse it again in 10 ml of ethanol. TEM characterization shows that the product is in the form of dispersed particles with a particle size of about 90 nm and a relatively uniform particle size. Figure 2 shown.

[0107] Example 12

[0108] (1) Add 150 mg of solid CaCl2, 5 mg of solid Mangostin and 100 ml of ethanol into a beaker, stir until fully dissolved, seal the beaker and evenly poke some small holes on the sealing film.

[0109] (2) Weigh 10 g of NH4HCO3 solid and place it on a six-well plate.

[0110] (3) Place the beaker and the six-well plate in the same vacuum dish and place it in a 37°C incubator for mineralization for 72 hours.

[0111] (4) Take out the beaker, centrifuge at 8000 rpm for 10 min, collect Mangostin@ACC and disperse it again in 10 ml of ethanol. TEM characterization shows that the product is in the form of dispersed particles with a particle size of about 90 nm and a relatively uniform particle size. Figure 2 shown.

[0112] Example 13

[0113] (1) Add 150 mg of solid CaCl2, 10 mg of solid Oxaliplatin and 100 ml of ethanol into a beaker and stir until fully dissolved. Then seal the beaker and evenly poke some small holes on the sealing film.

[0114] (2) Weigh 10 g of NH4HCO3 solid and place it on a six-well plate.

[0115] (3) Place the beaker and the six-well plate in the same vacuum dish and place it in a 37°C incubator for mineralization for 72 hours.

[0116] (4) Take out the beaker, centrifuge at 8000 rpm for 10 min, collect Oxaliplatin@ACC and disperse it again in 10 ml of ethanol. TEM characterization shows that the product is in the form of dispersed particles with a particle size of about 40 nm and a relatively uniform particle size. Figure 2 shown.

[0117] Embodiment 14

[0118] (1) Add 150 mg of CaCl2 solid, 10 mg of Paclitaxel solid and 100 ml of ethanol into a beaker, stir until fully dissolved, seal the beaker and evenly poke some small holes on the sealing film.

[0119] (2) Weigh 10 g of NH4HCO3 solid and place it on a six-well plate.

[0120] (3) Place the beaker and the six-well plate in the same vacuum dish and place it in a 37°C incubator for mineralization for 72 hours.

[0121] (4) Take out the beaker, centrifuge at 8000 rpm for 10 min, collect Paclitaxel@ACC and disperse it again in 10 ml of ethanol. TEM characterization shows that the product is in the form of dispersed particles with a particle size of about 120 nm and a relatively uniform particle size. Figure 2 shown.

[0122] Embodiment 15

[0123] (1) Add 150 mg of CaCl2 solid, 13.4 mg of CuCl2 solid, 10 mg of Doxorubicin (DOX) solid and 100 ml of ethanol into a beaker, stir until fully dissolved, seal the beaker and evenly poke some small holes on the sealing film.

[0124] (2) Weigh 10 g of NH4HCO3 solid and place it on a six-well plate.

[0125] (3) Place the beaker and the six-well plate in the same vacuum dish and place it in a 37°C incubator for mineralization for 72 hours.

[0126] (4) Take out the beaker, centrifuge at 8000rpm for 10min, collect Cu-ACC@Doxorubicin and disperse it again in 10ml ethanol. TEM characterization shows that the product is in the form of dispersed particles with a particle size of about 120nm and a relatively uniform particle size, as shown in Figure 3、 4.

[0127] (5) The DOX drug loading rate test result was 98%.

[0128] Example 16

[0129] (1) Add 150 mg of CaCl2 solid, 13.4 mg of CuCl2 solid, 39.3 mg of Co(NO3)2·6H2O solid and 100 ml of ethanol into a beaker, stir until fully dissolved, seal the beaker and evenly poke some small holes on the sealing film.

[0130] (2) Weigh 10 g of NH4HCO3 solid and place it on a six-well plate.

[0131] (3) Place the beaker and the six-well plate in the same vacuum dish and place it in a 37°C incubator for mineralization for 72 hours.

[0132] (4) Take out the beaker, centrifuge at 8000 rpm for 10 min, collect the CuCo-ACC and disperse it again in 10 ml of ethanol. TEM characterization shows that the product is in the form of dispersed particles with a particle size of about 280 nm and a relatively uniform particle size. Figure 5 shown.

[0133] (5) X-ray diffraction patterns show that the nanoparticles are amorphous calcium carbonate structures, such as Figure 7 shown.

[0134] Embodiment 17

[0135] (1) Add 150 mg of solid CaCl2, 9.5 mg of solid MgCl2, 18.4 mg of solid ZnCl2·4H2O and 100 ml of ethanol into a beaker, stir until fully dissolved, seal the beaker and evenly poke some small holes on the sealing film.

[0136] (2) Weigh 10 g of NH4HCO3 solid and place it on a six-well plate.

[0137] (3) Place the beaker and the six-well plate in the same vacuum dish and place it in a 37°C incubator for mineralization for 72 hours.

[0138] (4) Take out the beaker, centrifuge at 8000 rpm for 10 min, collect the CuCo-ACC and disperse it again in 10 ml of ethanol. TEM characterization shows that the product is in the form of dispersed particles with a particle size of about 101 nm and a relatively uniform particle size. Figure 6 shown.

[0139] (5) X-ray diffraction patterns show that the nanoparticles are amorphous calcium carbonate structures, such as Figure 7 shown.

Claims

1. A method for increasing drug loading rate by encapsulating metal ions in amorphous calcium carbonate (ACC), characterized in that: The method is: 1) dissolving calcium salt, metal salt and drug solid in ethanol at room temperature to obtain an ethanol solution of metal ion-drug-calcium; 2) pouring the solution obtained in step 1) into a beaker and sealing the beaker, wherein one or more ventilation holes are provided on the sealed beaker; 3) placing the ammonium bicarbonate solid and the beaker in step 2) in the same vacuum vessel; 4) Mineralization; 5) taking out the suspension in the beaker, centrifuging to obtain metal-drug-ACC particles and redispersing them in ethanol; the calcium salt is anhydrous calcium chloride; the concentration of the calcium salt in step 1) is 1.50 mg / ml; The amount of ammonium bicarbonate in step 3) is 10 g for each beaker in step 2); when there are multiple beakers in the same vacuum dish, the amount of ammonium bicarbonate is increased by a corresponding multiple and placed on the same six-well plate; The mineralization in step 4) is carried out at a constant temperature of 35-40° C. for 36-72 hours; The metal salt is copper chloride; the drug is doxorubicin hydrochloride.

2. The method according to claim 1, wherein the drug concentration in step 1) is 0.05 mg / ml-0.10 mg / ml.

3. The method according to claim 2, wherein the drug concentration in step 1) is 0.10 mg / ml.

4. The method according to claim 1, wherein the centrifugal speed in step 5) is 5000-10000 rpm and the time is 5-20 min.